Mr. Andre Larente reports

DIAGNOS SUCCESSFULLY COMPLETES THE RENEWAL OF US-FDA MEDICAL DEVICE ESTABLISHMENT REGISTRATION

The annual registration for Diagnos Inc.'s medical device establishment with the U.S. Food and Drug Administration has been completed.

Additionally, Diagnos would like to remind the reader that the legacy version of CARA, as a medical image management and processing system, remains cleared for commercialization in the United States.

The future version of CARA, which incorporates many other eye-related disease detection algorithms, is in the process of obtaining applicable regulatory approvals as detailed in the press release dated Jan. 13, 2026.

Diagnos also announces that it intends to amend the expiry date of 5,228,668 stock warrants issued as part of a non-brokered private placement of units initially announced on Oct. 25, 2024, and set to expire on April 25, 2026. The amended expiry date shall be Sept. 25, 2026. All other provisions of the warrants, such as the warrant exercise price of 40 cents per common share, shall remain unchanged and fully in effect during the extended exercise period.

The amendment to the warrants remains subject to the TSX Venture Exchange acceptance, as well as execution of formal documentation.

All moneys quoted in this press release shall be stated and paid in lawful money of Canada.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging artificial intelligence, Diagnos aims to provide more information to health care clinicians to enhance diagnostic accuracy, streamline workflows and improve patient outcomes on a global scale.

We seek Safe Harbor.